EMA Authorised: Enspryng (satralizumab) — Roche Registration GmbH

View source ↗

Summary

Authorised market approval of Enspryng (satralizumab) by Roche Registration GmbH for neuromyelitis optica in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica

Drugs mentioned

• Enspryng (satralizumab)

Snippet

Status: Authorised. Therapeutic area: Neuromyelitis Optica. MAH: Roche Registration GmbH. Decision date: 23/07/2026. Orphan medicine